Published in Drug Resist Updat on November 17, 2012
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget (2013) 1.09
Dietary ω -3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed Res Int (2013) 1.06
Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps. Oncogenesis (2015) 0.88
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84
Synthetic biology for therapeutic applications. Mol Pharm (2014) 0.78
Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy. Sci Rep (2014) 0.78
Multiscale analysis of the murine intestine for modeling human diseases. Integr Biol (Camb) (2015) 0.76
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One (2015) 0.75
Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med (2015) 0.75
SHP2, SOCS3 and PIAS3 Expression Patterns in Medulloblastomas: Relevance to STAT3 Activation and Resveratrol-Suppressed STAT3 Signaling. Nutrients (2016) 0.75
Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics (1943) 165.64
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Drug target identification using side-effect similarity. Science (2008) 9.24
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
SPONTANEOUS MUTATION TO STREPTOMYCIN RESISTANCE AND DEPENDENCE IN ESCHERICHIA COLI. J Bacteriol (1949) 7.70
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 6.56
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol (2010) 5.61
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer (2008) 5.35
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol (2011) 4.83
A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science (2005) 4.75
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer (2005) 4.16
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol (2011) 3.72
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A (2002) 3.71
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol (2009) 3.50
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell (2002) 3.13
Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science (1977) 2.88
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med (1948) 2.81
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2.57
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep (1964) 2.55
Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother (2011) 2.29
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Common effector processing mediates cell-specific responses to stimuli. Nature (2007) 2.20
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood (2005) 2.13
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97
Network medicine. FEBS Lett (2008) 1.84
Origin of the resistance of leukaemic cells to folic acid antagonists. Nature (1952) 1.77
Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol (2011) 1.76
Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data. J Comput Biol (2004) 1.61
Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst (1995) 1.60
Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci U S A (2011) 1.45
The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med (1973) 1.43
Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci U S A (2009) 1.37
What makes tumors multidrug resistant? Cell Cycle (2007) 1.34
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res (1995) 1.27
A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol (2010) 1.26
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24
A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood (1958) 1.23
RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res (2009) 1.21
Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol (2012) 1.20
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol (2008) 1.18
Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. Cancer Res (1952) 1.12
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res (2010) 1.06
Network-based drugs and biomarkers. J Pathol (2010) 1.01
Attempts at dual blocking of biochemical events in cancer chemotherapy. Cancer Res (1954) 0.92
Nek4 status differentially alters sensitivity to distinct microtubule poisons. Cancer Res (2010) 0.88
A comparison of the propensity for gene amplification between near-tetraploid and near-diploid V79 clones resistant to 150 nM methotrexate. Carcinogenesis (1996) 0.76
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Causal protein-signaling networks derived from multiparameter single-cell data. Science (2005) 34.28
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A (2006) 7.48
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A (2007) 4.80
A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science (2005) 4.75
Physicochemical modelling of cell signalling pathways. Nat Cell Biol (2006) 4.34
Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics (2005) 4.33
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell (2008) 3.88
The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell (2006) 3.57
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol (2009) 3.50
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol (2006) 3.01
Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol Syst Biol (2009) 2.98
DNA damage-mediated induction of a chemoresistant niche. Cell (2010) 2.94
Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol (2003) 2.85
A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell (2008) 2.65
Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol (2008) 2.63
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Mechanotransduction through growth-factor shedding into the extracellular space. Nature (2004) 2.48
Co-regulation of cell adhesion by nanoscale RGD organization and mechanical stimulus. J Cell Sci (2002) 2.42
A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates. Nat Methods (2005) 2.39
Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol (2002) 2.38
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Logic-based models for the analysis of cell signaling networks. Biochemistry (2010) 2.21
A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics (2005) 2.20
Common effector processing mediates cell-specific responses to stimuli. Nature (2007) 2.20
Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods (2010) 2.20
Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat Biotechnol (2002) 2.09
Computational model for cell migration in three-dimensional matrices. Biophys J (2005) 2.09
Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci (2011) 2.00
Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci U S A (2011) 2.00
In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet (2009) 1.99
Bayesian network approach to cell signaling pathway modeling. Sci STKE (2002) 1.96
Microfluidic shear devices for quantitative analysis of cell adhesion. Anal Chem (2004) 1.95
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal (2013) 1.92
Global network analysis of phenotypic effects: protein networks and toxicity modulation in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2004) 1.90
Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A (2010) 1.85
Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling. BMC Syst Biol (2009) 1.78
Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics (2010) 1.77
Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLoS Comput Biol (2006) 1.74
A biological approach to computational models of proteomic networks. Curr Opin Chem Biol (2006) 1.73
Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions. Biophys J (2005) 1.70
Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol (2009) 1.69
Genes and transposons are differentially methylated in plants, but not in mammals. Genome Res (2003) 1.66
A high-throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. Mol Cell Proteomics (2003) 1.61
Microarchitecture of three-dimensional scaffolds influences cell migration behavior via junction interactions. Biophys J (2008) 1.61
Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data. J Comput Biol (2004) 1.61
CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Syst Biol (2012) 1.60
Collecting and organizing systematic sets of protein data. Nat Rev Mol Cell Biol (2006) 1.58
Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci U S A (2002) 1.56
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell (2011) 1.55
Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C delta-dependent pathway. J Biol Chem (2004) 1.55
Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput Biol (2011) 1.53
Bayesian analysis of signaling networks governing embryonic stem cell fate decisions. Bioinformatics (2004) 1.52
Control of self-assembling oligopeptide matrix formation through systematic variation of amino acid sequence. Biomaterials (2002) 1.52
Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions. J Immunol (2005) 1.50
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol (2009) 1.49
The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell (2004) 1.48
Modeling and computational analysis of EGF receptor-mediated cell communication in Drosophila oogenesis. Development (2002) 1.47
Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol (2004) 1.46
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Flexible informatics for linking experimental data to mathematical models via DataRail. Bioinformatics (2008) 1.45
Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res (2011) 1.45
Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle (2009) 1.44
Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J Biol Chem (2004) 1.41
EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci (2007) 1.40
In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-α-induced apoptosis and proliferation by MAPKs. Sci Signal (2011) 1.37
Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci U S A (2005) 1.36
Growth factor-induced cell motility in tumor invasion. Acta Oncol (2002) 1.34
An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-alpha. Hepatology (2008) 1.30
Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. BMC Syst Biol (2012) 1.28
Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. Mol Biol Cell (2008) 1.27
Epidermal growth factor induces acute matrix contraction and subsequent calpain-modulated relaxation. Wound Repair Regen (2002) 1.27
Modeling of signal-response cascades using decision tree analysis. Bioinformatics (2005) 1.27
A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol (2010) 1.26
Quantitative network signal combinations downstream of TCR activation can predict IL-2 production response. J Immunol (2007) 1.26
2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J Cell Biol (2012) 1.26
Ligand accumulation in autocrine cell cultures. Biophys J (2005) 1.25
Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol (2008) 1.22
RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res (2009) 1.21
Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol (2012) 1.20
Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol (Camb) (2010) 1.20
Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A (2012) 1.19
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol (2008) 1.18
Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res (2003) 1.17
Multivariate proteomic analysis of murine embryonic stem cell self-renewal versus differentiation signaling. Proc Natl Acad Sci U S A (2004) 1.17
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.16
Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow. Exp Cell Res (2005) 1.15
Calpain proteases in cell adhesion and motility. Int Rev Cytol (2005) 1.14
Signaling thresholds govern heterogeneity in IL-7-receptor-mediated responses of naïve CD8(+) T cells. Immunol Cell Biol (2011) 1.14
Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res (2003) 1.14